

# Human HLA-DP (MHC Class II) Monomorphic Antibody

*Purified in vivo GOLD™ Functional Grade*

*Monoclonal Antibody*

## Product Information

**Product No.:** H260

**Clone:** B7/21

**RRID:** AB\_2737518

**Isotype:** Mouse IgG3

**Storage:** Sterile 2-8°C

## Product Description

### Specificity:

Clone B7/21 recognizes a monomorphic epitope on human HLA-DP1, -DP2, -DP3, -DP4, and -DP5. It does not cross-react with HLA-DR or HLA-DQ.

### Antigen Distribution:

HLA-DP is expressed on antigen-presenting cells, including macrophages, monocytes, DCs, and B cells, and activated T cells.

### Background:

HLA-DP antibody, clone B7/21, recognizes the major histocompatibility complex (MHC) class II molecule Human Leukocyte Antigen - DP isotype (HLA-DP). MHC class II is constitutively expressed on human professional antigen-presenting cells (APCs), including macrophages/monocytes, dendritic cells (DCs), and B cells, and is induced on T cells upon activation<sup>1</sup>. HLA-DP consists of two transmembrane proteins, a 35 kDa  $\alpha$  (heavy) chain and 29 kDa  $\beta$  (light) chain<sup>2</sup> encoded by the HLA-DPA1 and HLA-DPB1 genes, respectively, located in the HLA complex of chromosome 6. The N-terminal  $\alpha$ 1 and  $\beta$ 1 domains form the antigen-binding groove, which binds 13-25 aa peptides derived from exogenous antigens<sup>3</sup>. On APCs, MHC class II plays a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptide-MHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling<sup>4</sup>. It has also been demonstrated that MHC class II express on activated T cells are capable of antigen presentation<sup>5</sup> and can transduce signals into T cells, enhancing T cell proliferation and activity<sup>6</sup>. High HLA-DP expression is associated with an increased risk of graft-versus-host disease<sup>7</sup>. Specific alleles of HLA-DP are associated with autoimmune diseases, including rheumatoid arthritis<sup>8</sup>.

### Known Reactivity Species:

Human

### Format:

Purified *in vivo* in vivo GOLD™ Functional Grade

### Immunogen:

Unknown

## Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

## Purity

≥95% monomer by analytical SEC, >95% by SDS Page

## Endotoxin

< 1.0 EU/mg as determined by the LAL method

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

## Storage and Stability

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C.

## Avoid Repeated Freeze Thaw Cycles.

## Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using *in vitro* cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

## Applications

### Applications and Recommended Usage (Quality Tested By Leinco):

#### FC

### Other Applications Reported in Literature:

#### ICC

### Country of Origin

USA

## References

1. Holling TM, et al. (2004) Hum Immunol. 65(4):282-90.
2. Mitaksov V & Fremont DH. (2006) J Biol Chem. 281(15):10618-25.
3. Wieczorek M, et al. (2017) Front Immunol. 8:292.
4. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):16916-16921.
5. Barnaba V, et al. (1994) Eur J Immunol. 24(1):71-5.
6. Di Rosa F, et al. (1993) Hum Immunol. 38(4):251-60.
7. Petersdorf EW, et al. (2015) N Engl J Med. 373(7):599-609.
8. Raychaudhuri S, et al. (2012) Nat Genet. 44(3):291-6.